Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Men's Hormone Health

CoverageMen's Hormone Health

Does testosterone therapy increase prostate cancer risk?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·14 studies analyzed·2 core studies·Applies to: hypogonadal men

Bottom line

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Limited long-term cancer registry follow-up in treated populations.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

TRT and prostate cancer▼

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone. Surveillance remains standard.

Does testosterone therapy raise PSA?▼

Testosterone can raise PSA modestly; it does not appear to initiate or accelerate prostate cancer based on current trial data. PSA monitoring before and during TRT is standard practice.

Can you start TRT after prostate cancer treatment?▼

This is an active clinical debate. Some urologists offer TRT to appropriately selected men after curative treatment with no evidence of recurrence; shared decision-making and specialist input are required.

testosterone and prostate cancer risk▼

The saturation model suggests androgen receptors saturate at physiologic testosterone levels; raising testosterone above castrate levels does not appear to proportionally increase prostate cancer risk.

Testosterone prostate safety▼

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.

Does TRT increase prostate cancer risk?▼

Current systematic reviews and trial secondary analyses do not show a convincing increase in prostate cancer incidence among hypogonadal men treated with testosterone, though surveillance remains standard practice.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 13 relevant studies.

Overall finding

2 studies address sleep-related cognitive symptoms, with weighted findings showing a positive association. 3 studies address bone mineral density, with weighted findings showing no meaningful effect. 1 study addresses weight / body composition, with weighted findings showing unclear findings. 1 study addresses quality of life, with weighted findings showing unclear findings. 5 randomized or systematic-review reports and 8 observational studies address treatment. Testosterone therapy in hypogonadal men does not require categorical avoidance for prostate cancer history in all cases, but pretreatment evaluation, informed consent, and ongoing PSA and symptom surveillance remain standard.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Positive link

Sleep-related cognitive symptoms

high · 2 studies

2 studies address sleep-related cognitive symptoms, with weighted findings showing a positive association.

Mixed measurement

Studies

PMID 34536053PMID 35904664
Reassuring

Bone mineral density

moderate · 3 studies

3 studies address bone mineral density, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 19820017PMID 26901812PMID 11730247
Unclear

Weight / body composition

moderate · 1 study

1 study addresses weight / body composition, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 35904664
Unclear

Quality of life

moderate · 1 study

1 study addresses quality of life, with weighted findings showing unclear findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 35904664
Reassuring

Fractures

moderate · 1 study

1 study addresses fractures, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 19820017
Reassuring

Venous thromboembolism

limited · 1 study

1 study addresses venous thromboembolism, with weighted findings showing no meaningful effect. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 26205547

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 10. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Most studies agree on quality of life (unclear findings), while bone mineral density findings are no meaningful effect and more consistent across domains.

Supports main conclusion: 1 · Neutral / mixed: 12 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • The results indicated that OSA is significantly correlated with the decrease in serum testosterone levels in men.
  • Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton.
  • It has generally been held that estrogen and testosterone are the major sex steroids regulating bone metabolism in women and men, respectively.

Risks & harms

4 studies report safety-relevant findings. Design mix: Narrative review, Study design not clearly classified. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • Limited long-term cancer registry follow-up in treated populations.
  • Limited long-term cancer registry follow-up in treated populations.
  • Surrogate improvement does not prove a hard clinical outcome.

Clinical takeaway

Testosterone therapy in hypogonadal men does not require categorical avoidance for prostate cancer history in all cases, but pretreatment evaluation, informed consent, and ongoing PSA and symptom surveillance remain standard. Treat the man in front of you rather than applying population-level fear that the trial literature does not support for incident cancer risk.

Positive link

Sleep-related cognitive symptoms?

A positive association

high[34536053 · 35904664]

Reassuring

Bone mineral density?

No meaningful effect

moderate[19820017 · 26901812 · 11730247]

Unclear

Weight / body composition?

Unclear findings

moderate[35904664]

Unclear

Quality of life?

Unclear findings

moderate[35904664]

Reassuring

Fractures?

No meaningful effect

moderate[19820017]

Reassuring

Venous thromboembolism?

No meaningful effect

limited[26205547]

Unclear

Hematocrit / erythrocytosis?

Unclear findings

limited[35467476]

Unclear

Fertility / spermatogenesis?

Unclear findings

limited[27855957]

5 randomized or systematic-review reports and 8 observational studies address treatment. Weighted treatment findings show mixed findings.

5 RCT / systematic review · 8 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

12 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

14 analyzed studies

Strongest evidence

Expert opinion on drug safety2019

Landmark studyPMID 31495240

Safety of testosterone therapy in men with prostate cancer.

Introduction : The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has been shown to provide important symptomatic and general health benefits to men with testosterone deficiency (TD), including many men with PCa who may expect to live 30-50 years after diagnosis.

Review
Evidence
Relevance

Supporting literature

Association between obstructive sleep apnea and male serum testosterone: A systematic review and meta-analysis.

Obstructive sleep apnea and serum total testosterone: a system review and meta-analysis.

Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.

+9 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Hormone Health.

Does testosterone replacement increase cardiovascular risk?

Large randomized data (including TRAVERSE) do not show a significant increase in major adverse cardiovascular events with testosterone therapy in hypogonadal men over median follow-up of roughly three years. Older observational studies conflict, and absolute risk depends on baseline cardiovascular disease, formulation, and monitoring.

11 linked studies

Does testosterone therapy increase hematocrit and polycythemia risk?

Testosterone therapy commonly raises hematocrit; polycythemia is a recognized adverse effect requiring dose adjustment, formulation changes, or phlebotomy when thresholds are exceeded.

14 linked studies

Does testosterone therapy suppress fertility in men?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reliably reduces spermatogenesis. Recovery after discontinuation is variable and may be incomplete in some men.

14 linked studies

Does testosterone therapy increase venous thromboembolism risk?

Large observational cohorts suggest a modest increase in venous thromboembolism risk with testosterone therapy, particularly early after initiation. Absolute risk remains low in most populations but warrants attention in predisposed patients.

14 linked studies

Go deeper on Men's Hormone Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Men's Hormone HealthView pricing